MTHFD2 links RNA methylation to metabolic reprogramming in renal cell carcinoma.

One-carbon metabolism plays a central role in a broad array of metabolic processes required for the survival and growth of tumor cells. However, the molecular basis of how one-carbon metabolism may influence RNA methylation and tumorigenesis remains largely unknown. Here we show MTHFD2, a mitochondrial enzyme involved in one-carbon metabolism, contributes to the progression of […]

Reduced bleeding with DRY CUT® transurethral resection of the prostate (TURP) compared to standard TURP.

Objective: To compare bleeding and transfusion rate between patients who undergo standard transurethral resection of the prostate (TURP) and patients who undergo DRY CUT® TURP. Materials and methods: A retrospective comparison was made of 626 patients who underwent a standard monopolar TURP during 2004-2007 at the Karolinska University Hospital Huddinge with 620 patients who underwent […]

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.

Enzalutamide, a potent androgen-receptor inhibitor, has demonstrated significant benefits in metastatic and nonmetastatic castration-resistant prostate cancer. We evaluated the efficacy and safety of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC). ARCHES ( ClinicalTrials.gov identifier: NCT02677896 ) is a multinational, double-blind, phase III trial, wherein 1,150 men with mHSPC were randomly assigned 1:1 to enzalutamide (160 […]

Efficacy and Safety of Carboplatin Plus Paclitaxel as the First-, Second-, and Third-line Chemotherapy in Men With Castration-resistant Prostate Cancer.

Carboplatin and paclitaxel (CP) had shown moderate efficacy in treating castration-resistant prostate cancer (CRPC) before standard first-line docetaxel chemotherapy became available. Currently, for patients with homology-directed repair gene defects as well as for unselected patients, platinum chemotherapy is administered after all standard treatments have been ineffective. Here, we retrospectively studied the efficacy and safety of […]

A structured framework for optimizing high-intensity focused ultrasound ablative treatment in localized prostate cancer.

High-intensity focused ultrasound (HIFU) treatment has recently been pursued to reduce radical treatment-related morbidity in low-to-intermediate-risk localized prostate cancer (PCa), especially in older men. The aim of this study was to develop a dedicated framework for HIFU therapy. All clinical data, such as risk categories, magnetic resonance with functional parametric imaging, and histopathology, are essential […]

A Review of Ongoing Trials of Stereotactic Ablative Radiotherapy for Oligometastatic Cancers: Where Will the Evidence Lead?

Purpose: The oligometastatic state is a proposed entity between localized cancer and widely metastatic disease, comprising an intermediate subset of metastatic cancer patients. Most data to support locally-directed treatment, such as stereotactic ablative radiotherapy (SABR), for oligometastases are from retrospective institutional reports. Following the success of a recently completed and reported phase II trial demonstrating […]

ASCO 2019 43 Sarah Alaiwi

Sumanta Pal: Hi, I’m Monty Pal, the medical oncologist at the City of Hope Comprehensive Cancer Center Los Angeles and we’re here today on behalf of UroToday with a rising star in the field, actually a star already, Dr. Sarah Abou Alaiwi, who’s a fellow at the Dana Farber Cancer Institute. Sarah, welcome. Sarah Alaiwi: […]

ASCO 2019 42 Rana McKay

Sumanta Pal: Hi. My name’s Monty Pal. I’m a GU Medical Oncologist at the City of Hope Comprehensive Cancer Center in Southern California. We have two big hubs for renal cell, my shop and Dr. Rana Mckay’s shop down in UC San Diego. Rana, thanks for joining us. Rana Mckay: Thank you so much, Monty, […]

ASCO 2019 40 Ali Khaki mUC Check Inhibitors

Petros Grivas: Hello, I’m Petros Grivas, I’m an Associate Professor of Medicine at the University of Washington and Fred Hutchinson Cancer Research Center, and Medical Oncologist at the Seattle Cancer Care Alliance. I’m very fortunate today to be accompanied in this beautiful environment at ASCO by Dr. Ali Khaki. Ali is a superstar Fellow at […]

X